<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130077">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408641</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00047672 (UMD IRB#)</org_study_id>
    <nct_id>NCT01408641</nct_id>
  </id_info>
  <brief_title>Topiramate for Alcohol Use in Posttraumatic Stress Disorder</brief_title>
  <official_title>A 14-week Randomized, Placebo-controlled Study of Topiramate for Alcohol Use Disorders in Veterans With Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol abuse and dependence (alcohol use disorders, AUDs) and posttraumatic stress disorder
      (PTSD) are both prevalent in Veterans. Treating AUDs in Veterans with PTSD may be more
      difficult than treating AUDs in the general population. The FDA-approved medication
      topiramate has been shown to improve drinking outcomes in people with AUDs. Topiramate has
      also improved symptoms in people with PTSD. This study is designed to investigate whether
      topiramate will improve drinking outcomes in Veterans with PTSD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days of Heavy Drinking</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days Abstinent</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of PTSD Symptoms</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Memory/Cognitive Complaints</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Alcoholism</condition>
  <condition>Alcohol Abuse</condition>
  <condition>Alcohol Use Disorder</condition>
  <condition>PTSD</condition>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate arm will be titrated (dose will increase slowly) over 6 weeks to 400mg or highest tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Sugar Pill)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm will receive matching capsules without topiramate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules without topiramate</description>
    <arm_group_label>Placebo (Sugar Pill)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Ages 21-64

          -  Diagnosis of PTSD via a score of 50 or higher on the Clinician Administered PTSD
             Scale (CAPS)

          -  Alcohol abuse or dependence per diagnosis in the medical record -or- by consuming
             more than 35 standard drinks per week over the previous 4 weeks as measured by the
             Timeline Follow-Back Interview

          -  A desire to reduce drinking behavior

          -  Any Race/Ethnicity

        Exclusion Criteria:

          -  Currently taking a carbonic anhydrase inhibitor (e.g. zonisamide, acetazolamide,
             dichlorphenamide)

          -  Currently taking or have taken in the previous 3 months: acamprosate, naltrexone,
             disulfiram, topiramate

          -  Change in benzodiazepine dose within the previous 3 months

          -  Change in other (non-benzodiazepine) medication dose within the last 4 weeks

          -  Seizure disorder documented in the medical record

          -  Head trauma with loss of consciousness for greater than 30 minutes -or- a diagnosis
             of post-concussive syndrome documented in the medical record

          -  Suicide attempt within the previous 3 months or suicidal ideation within the previous
             4 weeks

          -  A history of kidney stones

          -  A history of glaucoma

          -  ALT or AST liver enzymes elevated more than twice the upper limit of normal

          -  More than 4 unsuccessful attempts at inpatient alcohol treatment

          -  Medically unstable (including significant hypertension despite adequate treatment)

          -  A history of delirium tremens (&quot;DTs&quot;) or alcohol withdrawal seizure

          -  Compulsory treatment to avoid legal consequences (e.g. imprisonment)

          -  Currently in a setting without access to alcohol (e.g. locked inpatient unit)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard A Fischer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Veterans Affairs, University of Maryland School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Duncan</last_name>
    <phone>(410)637-1432</phone>
    <email>Jennifer.Duncan5@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baltimore VA, VA Maryland Health Care System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernard A Fischer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 10, 2012</lastchanged_date>
  <firstreceived_date>August 1, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Bernard Fischer, MD</investigator_full_name>
    <investigator_title>Physician, Maryland Psychiatric Research Center, Outpatient Research Program</investigator_title>
  </responsible_party>
  <keyword>topiramate</keyword>
  <keyword>PTSD</keyword>
  <keyword>drinking</keyword>
  <keyword>alcohol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
